Uzan Catherine, Zanini-Grandon Anne-Sophie, Bentivegna Enrica, Gouy Sebastien, Leary Alexandra, Duvillard Pierre, Morice Philippe
Departments of *Gynecologic Surgery, †Oncology, and ‡Pathology, §University Paris Sud, Gustave Roussy Cancer Campus, Villejuif, France.
Int J Gynecol Cancer. 2015 Jun;25(5):830-6. doi: 10.1097/IGC.0000000000000437.
The aims of this study were to report the outcome of patients with advanced-stage serous borderline ovarian tumors (SBOT) after a first noninvasive recurrence and the impact of conservative treatment in that context and to define the best management for those patients.
From 1973 to 2006, 168 patients were treated at or referred to our institution for an SBOT with peritoneal implants. Their slides were reviewed by the same expert pathologist. Selection criteria were as follows: advanced stage (International Federation of Gynecology and Obstetrics ≥ II), with at least 1 recurrence (only noninvasive ones) and more than 5 years of follow-up.
Twenty patients met the inclusion criteria. The median duration of follow-up was 12 years (range, 6-23 years). Median age was 26 years (14-61 years). Initial surgical management was conservative for 14 patients and radical for 6. In the study population, 4 patients recurred, all with invasive disease. Time to invasive recurrence was at least 3 years for 3 of 4 patients. None of those 4 patients had a second-look surgery initially or after the first recurrence. Two patients had small-sized residual disease after initial management; only 1 of these 4 patients is currently alive and disease-free. There was no significant difference between conservative and radical treatment of the risk of second recurrence.
This study emphasizes the need for a long follow-up after recurrence of advanced-stage SBOT and the risk of a new invasive recurrence after a first noninvasive peritoneal recurrence. Conservative treatment does not seem as a risk factor and is still justified after a first noninvasive recurrence for young patients who desire to preserve fertility.
本研究旨在报告晚期浆液性交界性卵巢肿瘤(SBOT)患者首次非侵袭性复发后的结局以及保守治疗在此背景下的影响,并确定这些患者的最佳管理方案。
1973年至2006年期间,168例因SBOT伴腹膜种植而在我院接受治疗或转诊至我院的患者。他们的切片由同一位专家病理学家进行复查。入选标准如下:晚期(国际妇产科联盟≥II期),至少有1次复发(仅非侵袭性复发)且随访时间超过5年。
20例患者符合纳入标准。中位随访时间为12年(范围6 - 23年)。中位年龄为26岁(14 - 61岁)。14例患者初始手术管理为保守性,6例为根治性。在研究人群中,4例患者复发,均为侵袭性疾病。4例患者中有3例侵袭性复发时间至少为3年。这4例患者中没有1例在初始时或首次复发后进行二次探查手术。2例患者在初始治疗后有小残留病灶;这4例患者中目前仅1例存活且无疾病。保守治疗和根治性治疗在二次复发风险方面无显著差异。
本研究强调晚期SBOT复发后需要长期随访以及首次非侵袭性腹膜复发后出现新的侵袭性复发的风险。保守治疗似乎不是一个风险因素,对于希望保留生育能力的年轻患者,在首次非侵袭性复发后仍有其合理性。